Y Jessie Zhang

This study uses Fc-engineered antibodies to selectively engage FcγRIIa or FcγRI, revealing their distinct effector functions in human monocytes and macrophages.

This paper determines the structure of mouse FcγRIV and uses it to engineer a human Fc variant that enhances cross-species FcγR recognition.

This study shows Fc-silencing mutations in therapeutic antibodies do not block FCRL5 binding, potentially affecting B cell function through novel Fc-FCRL5 interactions.